Replies to post #764014 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gro,

Yes, NWBO’s platforms are “INCREDIBLE,” and additional clinical data are being collected today and will continue to be gathered moving forward…



BP is starting to recognize the “incredible” and vast potential of dendritic cell technology—from a Nobel Prize-winning discovery—especially in combination with checkpoint inhibitors ..PD-1 blockade technology also represents Nobel Prize-winning science!

The recent green light for the expansion of the pembrolizumab combo research at Roswell has brought some focus back on the Merck dot connecting (or other companies that make checkpoint inhibitors)…

Grant-funded trials are peer-reviewed, and the reviewers generally approve funding/expansion based on preliminary data. Notably, the PII trials at Roswell Park have been approved to expand in scope.. and look who joked on X about the overly-rigorous peer-review process for grant funding—the principal investigator of one of the Roswell trials!

Reviewers asking for prelim data when the grant mechanism says “prelim data not required” pic.twitter.com/qrBBnIvedt

— Sheheryar Kabraji (@SKabrajiMD) March 5, 2025

So, it looks like the grant peer reviewers have been watching the PII trials closely 🤔 …

Since the peer-reviewed Roswell trials include pembrolizumab, we are a bit curious about Merck’s interest and awareness of DC platforms and how emerging interim data might lead to new combo possibilities…

These three scientists have coauthored several publications on dendritic cell vaccines, and all three were recently recruited by Merck in 2023 and 2024:
☑️ Juraj Adamik
☑️ Paul Munson
☑️ Lisa H. Butterfield


https://acir.org/weekly-digests/2023/november/metabolic-characteristics-of-dc-vaccines-define-therapy-responses

https://www.nature.com/articles/s41467-023-42881-4

https://www.nature.com/articles/s41467-022-32849-1




https://www.sciencedirect.com/science/article/abs/pii/B9780128239018000030

Adamik and Butterfield are coauthors of this publication along with several University of Pittsburgh researchers:
https://rupress.org/jem/article/217/7/e20191369/151736/Impact-of-checkpoint-blockade-on-cancer-vaccine

Pawel Kalinski of Roswell Park and Lisa Butterfield are coauthors on this 2021 publication:
https://jitc.bmj.com/content/9/11/e003675

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456

Roswell DC Platform:


In addition to the expansion referenced above in a recent NWBO SEC filing, the other PII also had a recent change…

⭐️ Trial Update Published 27 Feb 2025:

https://clinicaltrials.gov/study/NCT04348747?a=29&b=30

The trial scope and title were expanded to include hormone receptor-positive (HR+) breast cancer, the most common subtype.

☑️ Increased Patient Eligibility: A broader population now qualifies.

☑️ Scientific Implications: Potential efficacy beyond TNBC and HER2+ cases, possibly due to shared immune mechanisms.

☑️ Regulatory & Market Impact: Broader applicability could enhance approval prospects and market potential.

☑️ Trial Design Adjustments: May involve new stratification to account for differences in tumor biology.

Dr. Kabraji recently mentioned and cited the pembrolizumab + DC vaccine trial in a passing comment on X in response to someone on another topic, but I found his comment insightful considering the date of his X reply post and the context of the recent trial updates…his post was just weeks before he became the principal investigator of that trial…

Ongoing clinical trial @RoswellPark led by @gandhi_shipra for pts with asymptomatic #bcsm brain mets has changed our practice. Can’t change therapy unless these patients are entered into trial but entry requires screening brain MRI https://t.co/3QlS0DgVgz

— Sheheryar Kabraji (@SKabrajiMD) February 1, 2025

[Steady_T]

You say that is if it makes a difference. SMH.

[sentiment_stocks]

As stated three trillion times… the company did not rework the entire protocol two weeks before data lock. They were working on the new protocol well over a year earlier as indicated in their Qs, Ks, and PRs. And when it was finally completed, they performed the data lock. This has been told to you multiple upon multiple times, and proof of this has been offered up in so many posts, but time and time again you choose to ignore it… rehashing this canard over and over as if it’s the god’s truth.

That instead is what’s incredible.